MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics...
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the...
WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve...
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Data from the recent 0.19 mg FAc implant Phase 4 observational real-world study were presented at the annual American Society...
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected...
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline...
DALLAS, July 26, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented...
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022JENA, Germany, July 26,...
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate...
Jane Wang, PhD, Apollomics, Chief Scientific Officer Jane Wang, PhD, Apollomics, Chief Scientific OfficerFOSTER CITY, Calif. and HANGZHOU, China, July...
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA,...
Renowned neuroscience leader to further long-term clinical research strategy and external collaborationsCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion...
Chiesi Group signed the HHS Health Care Sector Climate Pledge to achieve even greater progress on climate resilienceThe White House...
•Company’s novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic...
LAKE FOREST, Ill., July 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...